---
authors:
- Ebell, Mark H
category: Case Study
clinical_significance: High
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/39172682/
file_path: 2024/08/nirmatrelvir-ritonavir-does-not-significantly-reduce-symptom.md
issue: '2'
keywords:
- Middle Aged
- Male
- COVID-19 Drug Treatment
- Ritonavir
- SARS-CoV-2
- Female
- Humans
- Drug Combinations
- Hospitalization
- Adult
last_updated: '2025-07-30'
mesh_terms:
- Humans
- Ritonavir
- Hospitalization
- Male
- Female
- Middle Aged
- Drug Combinations
- COVID-19 Drug Treatment
- Adult
- SARS-CoV-2
- COVID-19 Vaccines
- COVID-19
- Unvaccinated Persons
original_format: PubMed
pages: '201'
patient_population: Adults
peer_reviewed: true
pmid: '39172682'
processed_date: '2025-07-30'
publication_date: '2024-08-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-08-10'
reading_time_minutes: 5
source: American family physician
specialty:
- Family Medicine
status: processed
tags:
- pubmed-enhanced
- clinical-review
- clinical-medicine
- family-practice
title: Nirmatrelvir/Ritonavir Does Not Significantly Reduce Symptoms or Hospitalization
  in Vaccinated High-Risk Patients and Unvaccinated Patients.
topics:
- Family Medicine
volume: '110'
publication_types: &id001
- Journal Article
pubmed_content_enriched: true
pubmed_full_data:
  pmid: '39172682'
  title: Nirmatrelvir/Ritonavir Does Not Significantly Reduce Symptoms or Hospitalization
    in Vaccinated High-Risk Patients and Unvaccinated Patients.
  authors:
  - last_name: Ebell
    fore_name: Mark H
    initials: MH
  journal_info:
    title: American family physician
    iso_abbreviation: Am Fam Physician
    volume: '110'
    issue: '2'
  publication_info:
    year: '2024'
    month: 08
    full_date: '2024-08-01'
  article_ids: {}
  mesh_terms:
  - descriptor: Humans
    major_topic: false
  - descriptor: Ritonavir
    major_topic: true
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Hospitalization
    major_topic: true
    qualifiers:
    - qualifier: statistics & numerical data
      major_topic: false
  - descriptor: Male
    major_topic: false
  - descriptor: Female
    major_topic: false
  - descriptor: Middle Aged
    major_topic: false
  - descriptor: Drug Combinations
    major_topic: false
  - descriptor: COVID-19 Drug Treatment
    major_topic: false
  - descriptor: Adult
    major_topic: false
  - descriptor: SARS-CoV-2
    major_topic: false
  - descriptor: COVID-19 Vaccines
    major_topic: false
    qualifiers:
    - qualifier: administration & dosage
      major_topic: false
  - descriptor: COVID-19
    major_topic: false
    qualifiers:
    - qualifier: prevention & control
      major_topic: false
  - descriptor: Unvaccinated Persons
    major_topic: false
  publication_types: *id001
related_articles:
- pmid: '39172682'
  title: Nirmatrelvir/Ritonavir Does Not Significantly Reduce Symptoms or Hospitalization
    in Vaccinated High-Risk Patients and Unvaccinated Patients.
  authors:
  - name: Ebell MH
    authtype: Author
    clusterid: ''
  source: Am Fam Physician
  pubdate: 2024 Aug
- pmid: '39269351'
  title: '[Nirmatreolvir-ritonavir (Paxlovid) leads to no reduction of symptoms or
    hospitalizations in vaccinated or unvaccinated high-risk adults with Covid-19.].'
  authors:
  - name: Kurotschka PK
    authtype: Author
    clusterid: ''
  - name: Ebell MH
    authtype: Author
    clusterid: ''
  - name: Serafini A
    authtype: Author
    clusterid: ''
  source: Recenti Prog Med
  pubdate: 2024 Sep
- pmid: '38411622'
  title: Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization
    in Adults With COVID-19.
  authors:
  - name: Shah MM
    authtype: Author
    clusterid: ''
  - name: Joyce B
    authtype: Author
    clusterid: ''
  - name: Plumb ID
    authtype: Author
    clusterid: ''
  - name: Sahakian S
    authtype: Author
    clusterid: ''
  - name: Feldstein LR
    authtype: Author
    clusterid: ''
  - name: Barkley E
    authtype: Author
    clusterid: ''
  - name: Paccione M
    authtype: Author
    clusterid: ''
  - name: Deckert J
    authtype: Author
    clusterid: ''
  - name: Sandmann D
    authtype: Author
    clusterid: ''
  - name: Hagen MB
    authtype: Author
    clusterid: ''
  - name: Gerhart JL
    authtype: Author
    clusterid: ''
  source: Clin Infect Dis
  pubdate: 2024 Jul 19
- pmid: '39696011'
  title: 'Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome
    in patients with SARS-CoV-2 infection: a real-life full-matched case-control study
    (SAVALO Study).'
  authors:
  - name: Gentile I
    authtype: Author
    clusterid: ''
  - name: Giaccone A
    authtype: Author
    clusterid: ''
  - name: Scirocco MM
    authtype: Author
    clusterid: ''
  - name: Di Brizzi F
    authtype: Author
    clusterid: ''
  - name: Cuccurullo F
    authtype: Author
    clusterid: ''
  - name: Silvitelli M
    authtype: Author
    clusterid: ''
  - name: Ametrano L
    authtype: Author
    clusterid: ''
  - name: Alf√® FA
    authtype: Author
    clusterid: ''
  - name: Pietroluongo D
    authtype: Author
    clusterid: ''
  - name: Irace I
    authtype: Author
    clusterid: ''
  - name: Chiariello M
    authtype: Author
    clusterid: ''
  - name: De Felice N
    authtype: Author
    clusterid: ''
  - name: Severino S
    authtype: Author
    clusterid: ''
  - name: Viceconte G
    authtype: Author
    clusterid: ''
  - name: Schiano Moriello N
    authtype: Author
    clusterid: ''
  - name: Maraolo AE
    authtype: Author
    clusterid: ''
  - name: Buonomo AR
    authtype: Author
    clusterid: ''
  - name: Scotto R
    authtype: Author
    clusterid: ''
  - name: Federico II COVID team
    authtype: CollectiveName
    clusterid: ''
  source: BMC Infect Dis
  pubdate: 2024 Dec 18
- pmid: '36508742'
  title: 'Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System
    : A Population-Based Cohort Study.'
  authors:
  - name: Dryden-Peterson S
    authtype: Author
    clusterid: ''
  - name: Kim A
    authtype: Author
    clusterid: ''
  - name: Kim AY
    authtype: Author
    clusterid: ''
  - name: Caniglia EC
    authtype: Author
    clusterid: ''
  - name: Lennes IT
    authtype: Author
    clusterid: ''
  - name: Patel R
    authtype: Author
    clusterid: ''
  - name: Gainer L
    authtype: Author
    clusterid: ''
  - name: Dutton L
    authtype: Author
    clusterid: ''
  - name: Donahue E
    authtype: Author
    clusterid: ''
  - name: Gandhi RT
    authtype: Author
    clusterid: ''
  - name: Baden LR
    authtype: Author
    clusterid: ''
  - name: Woolley AE
    authtype: Author
    clusterid: ''
  source: Ann Intern Med
  pubdate: 2023 Jan
---

# Nirmatrelvir/Ritonavir Does Not Significantly Reduce Symptoms or Hospitalization in Vaccinated High-Risk Patients and Unvaccinated Patients.

**Authors:** Ebell, Mark H

**Published in:** American family physician | Vol. 110, No. 2 | 2024-08-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/39172682/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Family Medicine

## MeSH Terms

Humans, Ritonavir, Hospitalization, Male, Female, Middle Aged, Drug Combinations, COVID-19 Drug Treatment, Adult, SARS-CoV-2, COVID-19 Vaccines, COVID-19, Unvaccinated Persons

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/39172682/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*
